Estimating the future burden of cardiovascular disease and the value of lipid and blood pressure control therapies in China

Table 3 Estimates of number of AMIs, strokes, and CVD deaths that could be prevented (2016–2030)

	AMIs averted (2016–2030)	Strokes averted (2016–2030)	CVD deaths averted (2016–2030)
Lipid management
Total population	9,718,958	7,822,617	3,359,026
At least one other CVD risk factor	8,861,135	6,955,115	3,034,802
> 55 years	7,847,580	6,798,342	3,039,769
> 65 years	5,330,256	5,124,158	2,497,361
Blood pressure management
Total population	12,690,319	24,090,474	7,322,172
At least one other CVD risk factor	11,705,084	21,439,156	6,570,986
> 55 years	10,850,141	21,062,444	6,822,105
> 65 years	7,150,355	14,382,099	5,453,613
Lipid and blood pressure management
Total population	19,621,753	29,640,863	9,713,259
At least one other CVD risk factor	18,020,822	26,371,553	8,730,106
> 55 years	16,431,006	25,878,475	8,982,422
> 65 years	10,932,970	18,007,273	7,226,067

The three targeted approaches to lipid and blood pressure management include (i) treating all those with hyperlipidemia with a measure of LDL-C >130 mg/dL and/or hypertensives with SBP > 140 mmHg who had at least one other CVD risk factor; (ii) treating all with a measure of LDL-C >130 mg/dL (and/or SBP >140 mmHg) and ages 55 years or older; and (iii) treating all with a measure of LDL-C >130 mg/dL (and/or SBP >140 mmHg) and ages 65 years or older. Data are based on authors’ calculations
AMI acute myocardial infarction, CVD cardiovascular disease

ISSN: 1472-6963